EFA Technologies News
4 articles
growth-positive
EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device
EFA Technologies, a pioneer in portable blood labs, has announced its entry into the Brazilian market with its flagship product, RevDx, following approval from Anvisa. The company also secured $6.5 million in funding from existing investors and new partners, including E-Health Ventures, Venturing Tech, ARC Impact Ventures, and the Israeli Innovation Authority. This funding will support product development, market expansion, and innovation in healthcare diagnostics. RevDx is a portable diagnostic device that offers rapid and accurate medical testing, revolutionizing on-site diagnostics. EFA Technologies aims to make Medtech accessible globally, starting with Brazil.
CustomersInvestmentExpand
growth-positive
Merchavia Expands Its Investments in Diagnostics: The Company to Invest NIS 1 Million in EFA - Engineering for All Ltd.
Merchavia Holdings and Investments, an Israeli investment company, is expanding its investments into the diagnostics sector. They will invest NIS 1 million in EFA, a company developing a device for accurate mobile blood counts and treatment decisions. The device aims to make treatment for infectious diseases more effective, save lives and costs, and reduce excessive antibiotic use. EFAs system is designed for easy operation and suitable for use in various settings. The investment aligns with Merchavias strategy of focusing on breakthrough technologies in large markets. The global diagnostics market is estimated to be worth $38 billion in 2022. EFA operates in the eHealth Ventures incubator, with partners including the Israel Innovation Authority, Maccabi Health Services, Medison, Cleveland Clinic, and Amgen.
Investment
growth-positive
Digital diagnostic lab co EfA raises $900,000
Israeli digital health technological incubator eHealth Ventures has invested $900,000 in its 8th portfolio company, Engineering for All (EfA). EfA, managed by Yoel Ezra, is developing RevDx, a lab-on-hand system that can enable fully automated, on-the-spot diagnostics and real-time disease mapping. The company is currently working on a functional prototype of the device. eHealth Ventures CEO Talor Sax has expressed excitement about the potential of the device and the experience of the EfA team.
Investment
growth-positive
eHealth Ventures Invests in "Engineering for All" - Disruptive Lab-on-a-Chip Diagnostic Device
eHealth Ventures has announced the acceptance of its 8th portfolio company, Engineering for All (EfA), which is developing a revolutionary Digital Diagnostic programable lab-on-hand system. eHealth Ventures has invested $900,000 in EfAs seed financing round. The system aims to provide fully automated, on-the-spot gold standard microscopy diagnostics and real-time disease mapping. It includes capabilities for complete blood count (CBC) and parasitology, diagnosis of infectious diseases, and affordable test-treat-track treatment. The company has won awards in Israel and presented with delegations in India and Taiwan. The goal is to address the lack of access to healthcare for a billion people and reduce misdiagnosis and overuse of antibiotics. eHealth Ventures sees the potential of RevDx as a game-changing solution.
Investment
